Beximco Pharmaceuticals (BXP) Q1 24/25 earnings summary

Executive summary

• Net revenue for July–September 2024 rose to Tk 11,713.9 million (consolidated), up 5% year-over-year; standalone revenue reached Tk 9,765.0 million, up 5.6% year-over-year.

• Consolidated net profit after tax increased 7.9% year-over-year to Tk 1,691.9 million; standalone net profit rose 11.1% to Tk 1,612.4 million.

• Earnings per share (EPS) improved to Tk 3.77 (consolidated) and Tk 3.61 (standalone), compared to Tk 3.48 and Tk 3.25, respectively, in the prior year.

Financial highlights

• Consolidated gross profit margin increased to 46.2% from 44% year-over-year; standalone gross margin was 45.9%.

• Operating profit (consolidated) rose 11% year-over-year to Tk 2,563.1 million; standalone operating profit up 15.7% to Tk 2,303.7 million.

• Net asset value (NAV) per share increased to Tk 111.25 (consolidated) and Tk 109.85 (standalone), up from Tk 101.40 and Tk 100.41, respectively.

• Net operating cash flow per share declined to Tk 3.80 (consolidated) and Tk 3.15 (standalone), compared to Tk 6.07 and Tk 5.74 last year.

Outlook and guidance

• Board recommended 40% cash dividend (Tk 4.00 per share) for Beximco Pharma, 50% for Nuvista Pharma, and 10% for Synovia Pharma, all subject to shareholder approval.